Global Radiopharmaceuticals Market Competitive Strategies and Forecasts to 2031Posted by ramtbrc on November 15th, 2022 Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies! The Radiopharmaceuticals Global Market Report 2022-31 by The Business Research Company describes and explains the global radiopharmaceuticals market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region. The Radiopharmaceuticals Global Market Opportunities And Strategies Report covers radiopharmaceuticals market drivers, radiopharmaceuticals market trends, radiopharmaceuticals market segments, radiopharmaceuticals market growth rate, radiopharmaceuticals market major players, radiopharmaceuticals market size and a special focus on identifying the trends, opportunities, and strategies that can lead to success. Request for the report sample: The Radiopharmaceuticals Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies in detail. O&S reports are available off the shelf and can be delivered to clients on the day of purchase. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
View more on the Radiopharmaceuticals Market Report: https://www.thebusinessresearchcompany.com/report/radiopharmaceuticals-global-market A key radiopharmaceuticals market trend: Research collaborations and partnerships are gaining significant popularity in the radiopharmaceuticals market over recent years. Major companies operating in the radiopharmaceuticals market are collaborating with other industry players to conduct R&D activities to expand their business. For instance, in March 2020, Debiopharm, a Switzerland-based biopharmaceutical company, signed a research agreement with 3B Pharmaceuticals (3BP), a Germany-based biotechnology firm, to develop the Debio 0228 radioligand program, targeting the CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer. The report covers the radiopharmaceuticals market segments: 2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinnology, Neurology, Nephrology, Others 3) By End User: Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others About The Business Research Company: Contact Information: Asia: +91 88972 63534 Americas: +1 315 623 0293 Like it? Share it! More by this author |